Rhythm Biosciences Limited

ASX:RHY Stock Report

Market Cap: AU$27.4m

Rhythm Biosciences Management

Management criteria checks 0/4

We currently do not have sufficient information about the CEO.

Key information

David Atkins

Chief executive officer

AU$705.2k

Total compensation

CEO salary percentage49.63%
CEO tenure1.5yrs
CEO ownership1.2%
Management average tenureno data
Board average tenure1.2yrs

Recent management updates

Recent updates

Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

Dec 06
Is Rhythm Biosciences (ASX:RHY) In A Good Position To Deliver On Growth Plans?

We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

Aug 09
We're Not Very Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Rate

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Apr 11
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Dec 02
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Jul 19
We're Hopeful That Rhythm Biosciences (ASX:RHY) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Mar 03
Here's Why We're Not Too Worried About Rhythm Biosciences' (ASX:RHY) Cash Burn Situation

Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

Dec 03
Do Institutions Own Rhythm Biosciences Limited (ASX:RHY) Shares?

CEO Compensation Analysis

How has David Atkins's remuneration changed compared to Rhythm Biosciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2025AU$705kAU$350k

-AU$4m

Mar 31 2025n/an/a

-AU$3m

Dec 31 2024n/an/a

-AU$2m

Sep 30 2024n/an/a

-AU$5m

Jun 30 2024AU$409kAU$49k

-AU$7m

Compensation vs Market: David's total compensation ($USD458.91K) is above average for companies of similar size in the Australian market ($USD294.41K).

Compensation vs Earnings: David's compensation has increased whilst the company is unprofitable.

CEO

David Atkins (60 yo)

1.5yrs
Tenure
AU$705,209
Compensation

Dr. David Atkins, MBA, Ph. D., serves as Chief Executive Officer of Rhythm Biosciences Limited since May 13, 2024 and served as its Managing Director until July 2025 and serves as its Director since Septem...

Board Members

NamePositionTenureCompensationOwnership
David Atkins
CEO & Director1.2yrsAU$705.21k1.24%
A$ 340.0k
Susan MacLeman
Independent Non-Executive Director2.8yrsAU$66.88kno data
Gavin Fox-Smith
Independent Non-Executive Directorless than a yearAU$30.63kno data
Finlay Macrae
Member of Clinical Advisory Boardno datano datano data
Jon Emery
Member of Clinical Advisory Boardno datano datano data
Sally Benton
Member of Clinical Advisory Boardno datano datano data
1.2yrs
Average Tenure

Experienced Board: RHY's board of directors are not considered experienced ( 1.2 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/11/06 01:35
End of Day Share Price 2025/11/06 00:00
Earnings2025/06/30
Annual Earnings2025/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Rhythm Biosciences Limited is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Stuart RobertsPitt Street Research Pty Ltd.